Cargando…
The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS‐BPH)
Studies have shown that 48.59% of benign prostate hyperplasia (BPH) is combined with metabolic syndrome (MetS). The mainstream view supports the correlation between MetS and BPH, but the pathogenesis of MetS‐BPH is not fully understood. Four hundred and seventy‐four men, aged 47 years or older, were...
Autores principales: | Chen, Z.P., Yan, Y., Chen, C.J., Li, M., Chen, C., Zhao, S.C., Song, T., Liu, T., Zou, C.H., Xu, Q., Li, X. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646917/ https://www.ncbi.nlm.nih.gov/pubmed/29873201 http://dx.doi.org/10.1111/andr.12498 |
Ejemplares similares
-
Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH)
por: Sciacqua, L. V., et al.
Publicado: (2023) -
Association of the CYP19A1 rs700518 Polymorphism with Selected Markers of Bone Metabolism in Women with Hyperandrogenism
por: Uzar, Izabela, et al.
Publicado: (2022) -
Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)
por: Cambio, Angelo J, et al.
Publicado: (2007) -
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
por: Foo, Keong Tatt
Publicado: (2019) -
Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events
por: Ko, Young Hwii, et al.
Publicado: (2010)